Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 29, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital transactions.
- Shares Purchased: 4,314,000 ordinary shares of 25 pence each.
- Purchase Price: 1,106.383 pence per share.
- Treasury Shares Held: 504,194,158 shares (representing 9.22% of total voting rights).
- Shares in Issue: 5,469,727,160 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 4,314,000 repurchased shares. Consequently, the total number of shares in issue decreased to 5,469,727,160. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,469,727,160) for accurate calculation of ownership percentages under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (504,194,158) and its impact on total voting rights (9.22%).
- Note that this filing is a notification of a share buyback execution and does not contain quarterly or annual financial results.